With the success of Lecanemab and Donanemab motivating more companies than ever to follow suit, and big pharma investments, such as Abbvie’s $8.7 billion acquisition of Cerevel, emphasizing neuroscience prioritization, momentum in Alzheimer’s and Parkinson’s research is at an all-time high.

This March, connect with an exclusive group of 150+ senior decision makers at the 13th Alzheimer’s & Parkinson’s Drug Development Summit, from large pharma heavyweights to well-established and new, innovative biotechs. In a field where biopharma trusts their long-established partners, seize the opportunity to stand out in a competitive market and showcase your distinctive value proposition.

There are a limited number of partnerships available, including speaking positions across the full agenda, reserved exclusively for high-quality companies. If you provide services in assay development, neuroimaging, drug discovery, in vitro or in vivo modelling, or clinical research that would benefit this niche audience of CNS decision-makers, now is the time to secure new business and form lasting connections with the companies seeking solutions to progress their Alzheimer’s and Parkinson’s drug products to market.